In particular, this study aimed to define the ability of AFP, AFP-L3, and PIVKA-II assays to detect HCC among patients with early-stage HCV-induced HCC, as well as to compare with patients with HCV-related cirrhosis used as a control group. The gene discussed is AFP; the disease is hepatocellular carcinoma.